Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology
March 31st, 2022
2.9K views
Field-effect biosensing (FEB) is a label-free technique for detecting biomolecular interactions. It measures the electric current through the graphene biosensor to which the binding targets are immobilized. The FEB technology was used to evaluate biomolecular interactions between Hsp90 and Cdc37 and a strong interaction between the two proteins was detected.
Overview
Field-effect biosensing (FEB) is a label-free technique for detecting biomolecular interactions, measuring electric current through a graphene biosensor. This study evaluates the interaction between Hsp90 and Cdc37, revealing a strong binding between the two proteins.
Key Study Components
Area of Science
- Neuroscience
- Biochemistry
- Biophysics
Background
- FEB is a cost-effective platform for biomolecular interaction detection.
- It provides fast and accurate measurements.
- The technology is user-friendly, requiring minimal training.
- Applications include drug validation and biomolecular analysis.
Purpose of Study
- To validate known and unknown biomolecular interactions.
- To test potential inhibitors of these interactions.
- To optimize experimental conditions for reliable results.
Methods Used
- Label-free detection using FEB technology.
- Automated software guiding users through experiments.
- Chip functionalization and buffer exchange optimization.
- Measurement of binding interactions between proteins.
Main Results
- Strong interaction detected between Hsp90 and Cdc37.
- Successful validation of the FEB method for protein interactions.
- Demonstrated ease of use for researchers.
- Potential for diverse applications in pharmaceuticals.
Conclusions
- FEB is an effective tool for studying biomolecular interactions.
- It can facilitate drug development and validation processes.
- Proper experimental setup is crucial for reliable outcomes.
Frequently Asked Questions
What is FEB?
FEB stands for field-effect biosensing, a technique for detecting biomolecular interactions without labels.
How does FEB work?
It measures electric current through a graphene biosensor where binding targets are immobilized.
What are the advantages of using FEB?
FEB is cost-effective, user-friendly, and provides fast, accurate measurements of biomolecular interactions.
What types of applications can FEB be used for?
It can be applied in pharmaceuticals, biomolecular analysis, and drug validation.
What challenges might beginners face with FEB?
Choosing the right analyte concentrations and optimizing the chip functionalization process can be challenging.
Executive Industry Relevance
Field-effect biosensing (FEB) enables rapid, label-free quantification of protein-protein interactions, supporting early-stage target validation and mechanistic de-risking in biopharma R&D. By delivering nanomolar-range affinity data for complexes such as Hsp90/Cdc37, FEB strengthens predictive confidence at critical discovery inflection points. This platform offers scalable, reproducible measurement capabilities that inform portfolio triage and downstream screening strategies.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Quantifies direct binding affinities between molecular chaperones and client proteins to clarify pathway dependencies.
- Enables functional validation of disease-relevant protein complexes implicated in oncology and other therapeutic areas.
- Supports mechanistic de-risking by distinguishing specific versus nonspecific interactions in target selection.
- Provides quantitative KD values to inform go/no-go decisions in target nomination.
Screening & Assay Development
- Delivers validated, label-free readouts suitable for inhibitor or modulator screening against protein-protein interactions.
- Facilitates assay standardization and reproducibility through automated, user-guided workflows.
- Generates quantitative outputs (I-response, KD) that enable reliable compound evaluation and ranking.
- Supports platform reuse for diverse protein, peptide, and small molecule interaction studies.
Translational & Preclinical Research
- Aligns in vitro binding data with disease-relevant chaperone-kinase pathways implicated in malignancy.
- Enables continuity from discovery-stage interaction validation to preclinical inhibitor assessment.
- Reduces translational risk by providing robust, quantitative interaction data for biomarker and target engagement studies.
Pipeline & Workflow Integration
FEB technology integrates at the interface of early discovery and lead identification, providing a reusable platform for hypothesis testing, screening, and preclinical validation.
- Discovery Biology: Supports hypothesis-driven interrogation of protein interaction networks and pathway mapping.
- Screening: Offers reproducible, quantitative affinity measurements for assay development and compound triage.
- Analytics: Delivers automated KD calculations and real-time I-response data for robust statistical comparison.
- Translational Research: Bridges in vitro interaction data with disease-relevant pathway modulation.
- Enterprise Reuse: Provides a scalable, label-free detection platform adaptable across multiple targets and modalities.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target validation.
- Operational Value: Enhances standardization, reproducibility, and scalability of interaction assays.
- Strategic Value: Enables informed go/no-go decisions and capital-efficient portfolio advancement.
- Portfolio Impact: Supports risk-adjusted prioritization and cross-program data comparability.
Implementation Considerations
- Requires expertise in protein handling, pipetting, and biosensor chip functionalization.
- Needs access to FEB instrumentation and compatible analytical software for automated data analysis.
- Demands careful optimization of analyte concentrations and buffer conditions for reliable KD determination.
- Standardization of timing and handling steps is critical for reproducibility across users and teams.
- Adaptation to new targets may require protocol adjustments and validation of chip chemistry.
Biopharma FAQs
Why does null hypothesis testing matter for Hsp90/Cdc37 interaction validation?
Null hypothesis testing ensures that observed binding between Hsp90 and Cdc37 is statistically significant and not due to random association, supporting robust target validation. This approach underpins confidence in mechanistic relevance for downstream R&D decisions.
How does independent variable isolation fit the FEB discovery workflow?
By systematically varying Cdc37 concentrations while holding other conditions constant, FEB enables precise measurement of binding responses, isolating the effect of the analyte on Hsp90 interaction. This isolation is essential for accurate affinity determination and screening readiness.
What do quantitative I-response and KD measurements enable in biopharma pipelines?
Quantitative I-response and KD outputs provide actionable data for ranking interaction strengths, guiding compound screening, and informing target engagement thresholds. These metrics support data-driven advancement and portfolio triage.
Why are replication requirements critical for cross-functional collaboration in FEB assays?
Replication across independent experiments ensures reproducibility and reliability of affinity measurements, enabling cross-team confidence in assay outputs and facilitating collaborative decision-making in multi-disciplinary R&D environments.
What statistical analysis capabilities are required before implementing FEB-based screening?
Automated analysis software must generate KD values, fit binding curves, and provide real-time I-response data to support robust statistical evaluation. These capabilities are essential for validating assay performance and enabling high-confidence screening workflows.
Chapters in this video
0:04
Introduction
1:16
Chip Activation
2:09
Target Protein Immobilization
3:09
Preparing Analyte Samples and Running the Experiment
6:09
Analysis
6:43
Results: Data Files Generated from Hsp90 and Cdc37 Interaction Using FEB System (Experiment 1 and 2) and ITC Analysis
8:39
Conclusion
